Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-20
2006-06-20
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07064127
ABSTRACT:
Disclosed herein is a method for treating hepatic fibrosis comprising administering to a patient in need of such treatment an amount effective to treat hepatic fibrosis of imatinib mesylate. This is based on the ability of imatinib mesylate to down regulate stellate cell activation in culture and in vivo. Hepatic fibrosis is not limited to patients with chronic Hepatitis B, Hepatitis C, non-alcoholic steatophepatitis (NASH), alcoholic liver disease, metabolic liver diseases (Wilson's disease, hemochromatosis), biliary obstruction (congenital or acquired) or liver diseases associated with fibrosis of unknown cause.
REFERENCES:
patent: 6872715 (2005-03-01), Santi et al.
patent: 2003/0147813 (2003-08-01), Lyons
patent: 2003/0203846 (2003-10-01), Srivastava et al.
patent: 2004/0121971 (2004-06-01), Chen et al.
patent: 2005/0261283 (2005-11-01), Sukhatme
Kinnman, Laboratory Investigation, vol. 83, No. 2, Feb. 2003, “The Myofibroblastic Conversion of Peribiliary Fibrogenic Cells Distinct from Hepatic Stellate Cells is Stimulated by Platelet-Derived Growth Factor During Liver Fibrogenesis”, pp. 163-173.
Albanis Efsevia
Friedman Scott
Darby & Darby
Henley III Raymond J.
Mount Sinai School of Medicine of New York University
LandOfFree
Treatment of hepatic fibrosis with imatinib mesylate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatic fibrosis with imatinib mesylate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatic fibrosis with imatinib mesylate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3705003